More serious risks are more intense abdominal pain, persistent vomiting, and severe dehydration
Retatrutide is a next-generation weight loss injection developed by Eli Lilly (same manufacturer as Mounjaro), designed to target three separate hormone receptors in the body: the GLP-1 receptor, the GIP receptor, and the glucagon receptor
Any downstream effects, whether on energy, cognition, or ordinary metabolic housekeeping, run through the enzymatic and receptor pathways that pharmacology has already mapped in peer-reviewed literature
All opinions and descriptions are based on publicly available information, ingredient-level research, and brand marketing materials
Metabolic Very common (10% or more): Hypoglycemia (up to 29.8%), decreased appetite (up to 14%) Common (1% to 10%): Severe hypoglycemia Hypoglycemia (blood glucose less than 54 mg/dL or 3 mmol/L) has commonly been reported in patients with type 2 diabetes